Skip to main navigation

About
Technology
How It Works
Pipeline
Partners
Contact
Careers
Investors

News Releases

Year

Rani Therapeutics Announces Research and Development Collaboration with PegBio to Expand Obesity Pipeline Across Multiple Novel Candidates

Jul 09, 2026

Rani Therapeutics Appoints Nicholas Maestas as Chief Financial Officer

Jun 29, 2026

Rani Therapeutics Holdings, Inc. Announces Pricing of $20.0 Million Registered Direct Offering of Class A Common Stock Priced At-The-Market Under Nasdaq Rules

May 26, 2026

Rani Therapeutics Reports First Quarter 2026 Financial Results; Provides Corporate Update; Announces CFO Transition

May 15, 2026

Rani Therapeutics to Participate in the H.C. Wainwright Annual BioConnect Investor Conference

May 12, 2026

Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy

Apr 09, 2026

Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update

Mar 26, 2026

Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization

Mar 25, 2026

Rani Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results

Mar 19, 2026

Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer

Jan 28, 2026

Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill® for the Treatment of Obesity in Collaboration with ProGen

Jan 08, 2026

Print Page
Email Alerts
RSS Feeds
Contact IR

A clinical-stage biotech company developing the RaniPill® platform for the oral delivery of biologic drugs.

NASDAQ: RANI

Company

About Us
Leadership
Careers
Contact

Science

RaniPill Technology
Pipeline
Partners

Investor

News & Events
Stock Information
Corporate Governance
Financials & Filings
IR Resources

© 2026 Rani Therapeutics, LLC. All rights reserved.

Privacy Policy